Needham downgraded Biogen Inc (NASDAQ:BIIB), citing limited catalysts for the company over the next year. Alzheimer’s drug ...

After the unexpected success of their PHOENYCS GO study for dapirolizumab pegol in lupus earlier this fall, Biogen and UCB ...

UCB and Biogen (BIIB) presented detailed results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab pegol, or DZP, a novel Fc-free anti-CD40L drug candidate, demonstrating significant ...

(RTTNews) - UCB and Biogen Inc. (BIIB) presented detailed results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab pegol, a Fc-free anti-CD40L drug candidate, showing significant clinical ...

Medline today announced that it has expanded its medical surgical prime vendor agreement with Northern California-based ...

Stephen Abreu has been appointed by the Board as Executive Director. He will lead the organization's overall strategy and ...

CareMessage, the largest patient activation platform in the United States for underserved populations, today announced the launch of their AI Assistant, adding ethical AI tools to their market-leading ...

Investing.com - Needham downgraded Biogen Inc (NASDAQ:BIIB) on Monday, citing slower-than-expected growth for its Alzheimer's ...

Stocks climbed as Treasuries halted a selloff that drove 10-year yields near 4.5%, with traders keeping a close eye on news ...

The European Commission (EC) has approved OPUVIZ 40 mg/mL solution for injection in a vial. OPUVIZ is a biosimilar referencing Eylea (aflibercept). The biosimilar has been developed and registered by ...

And this corruption even extends into the Food and Drug Administration (FDA). Three years ago, Biogen got the FDA to approve its Alzheimer drug Aduhelm, even though there was little proof of its ...

Within 10 years of Crohn's disease diagnosis, up to 50% of people will require surgery, with ileocaecal or ileocolonic resection being the most common procedure.1 Surgery is not curative and disease ...